PERKINELMER TO COMBINE WITH BIOLEGEND, ACCELERATING LEGENDARY DISCOVERIES

Transaction Features

- Purchase price of $5.25B; $2.2B stock consideration with remainder from new debt and cash on hand, committed to remain investment grade
- Enhanced combined company growth and margin profile with expected $0.30 adj. EPS accretion in Year 1 and >$0.50 in Year 2
- High single-digit adj. ROIC anticipated by Year 6
- Expected to close by end of 2021

“We are thrilled to have the opportunity to bring our technologies and innovative cultures together to create seamless solutions to push science and discovery forward. We believe the joining of our teams poses a very exciting opportunity to accelerate discoveries in fast growing markets which will help life science researchers leverage ever developing technologies and novel approaches to better understand and fight disease.”

Prahlad Singh
President and Chief Executive Officer, PerkinElmer Inc.

BioLegend: Global Innovator of Antibodies & Reagents

$380M 2022e Revenue
100% Recurring Revenue
Accretive Margin Profile

Revenue Split
55% North America
25% Europe & ROW
20% Asia Pacific

>700 Employees
10K Customers
130 Countries

Global Reagents Center of Excellence for Legendary Discovery

Headquarters in San Diego, CA

Strategic Rationale

- Further expands PKI in fast growing markets such as biologics, cell and gene therapy, proteogenomics, and recombinant proteins and increases PKI’s overall mix of recurring and higher margin revenue
- BioLegend’s San Diego HQ to become content development engine for life science reagents and accelerate NPIs in high-growth opportunities
- Will increase clinical impact by leveraging PKI’s position in diagnostics and broad commercial reach
- Further accelerates financial profile of combined company by adding 100 bps of organic growth and 300 bps of higher operating margin

Leading Global Player in Antibody & Research Reagents

PKI and BioLegend: Combined Research Portfolio

~$700M 2022e Revenue
+LDD Projected Growth